$RCKT

Rocket amended its complaint against UWM, alleging UWM breached agreements by targeting Mr. Cooper borrowers for refinancing, causing prepayment rates 2.5x higher. Rocket claims $100M in damages, citing UWM's initiatives like Refi75 and KEEP. UWM denies allegations, calling them baseless. Rocket acquired Mr. Cooper for $14.2B in 2025.

Rocket Mortgage launched the 'Moving Squad' program to attract brokers from UWM, offering a $10,000 bonus for referrals. The program provides onboarding support. UWM criticized Rocket's strategy, emphasizing its technology and service. UWM reported a $451.9M Q2 loss and a $2.05B equity investment. Rocket's leadership highlighted growth opportunities in the broker channel. Niemiec accused UWM of mismanagement and higher pricing.

Rocket Mortgage amended its lawsuit against United Wholesale Mortgage (UWM), alleging UWM violated non-solicitation agreements by targeting 182,000 loans worth $65B in unpaid principal. Rocket claims UWM recaptured over 15,500 loans, with 48% refinanced through UWM, and seeks at least $100M in damages. The lawsuit cites UWM's financial pressures and programs like Refi75 and Refi Shield 100 as motives.

ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Severance and Change in Control Program On August 21, 2026, the Board of Directors (the “Board”) of Rocket Pharmaceuticals

Rocket Mortgage promotes home equity loans to pay off credit card debt, citing lower interest rates. U.S. credit card debt rose to $1.263 trillion in Q2 2026, while home equity reached $17.9 trillion. Rocket's campaign targets high-interest debt, but experts warn of risks, including potential home loss if loans aren't repaid. Alternatives like debt consolidation loans or balance transfer cards are suggested.

Stevens Christopher James (Chief Operating Officer) sold 36,658 shares of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.50 ($0.13M total) on 2026-08-11.

ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress All three initial patients treated with RP-A501 under the modified pivotal Phase 2 protocol completed the protocol-defined safety observation period; no thrombotic mic

Rocket Pharmaceuticals said its RP-A501 Danon disease gene therapy has safely treated three Phase II patients after an FDA-triggered protocol change. The FDA allowed relaunch of NCT06092034 in Aug 2025. Rocket reports no capillary leak syndrome, blood vessel damage, or other serious adverse events since dosing with a recalibrated dose plus rituximab, sirolimus, and corticosteroids.

Investing.com reports Rocket Pharmaceuticals (RCKT) rose 0.6% pre-open after it said the first three patients treated under a revised Phase 2 protocol for RP-A501 Danon disease gene therapy showed no significant safety issues, including no thrombotic microangiopathy or capillary leak syndrome. The FDA lifted the clinical hold in mid-2025. Shares were $3.13 ahead of Aug 6 Q2 2026 earnings.

ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001281895 0001281895 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2026 R